Font: Financial Modeling Prep • Jan 08, 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is known for its innovative approach to treating conditions like depression and migraines. In a competitive landscape, Axsome stands out with its unique drug pipeline and strategic partnerships.
On January 7, 2026, Herriot Tabuteau, the CEO and a significant shareholder of Axsome, sold 31,261 shares at $170.38 each. This transaction reduced his holdings to 7,229 shares. This move follows a similar transaction by Director Mark Saad, who sold 37,577 shares at $165.18 each on December 31st, reducing his ownership by 78.98% to 10,002 shares.
Axsome's stock opened at $178.69 recently, with a current price of $170.69, reflecting a slight decrease of 0.69%. The stock has traded between $168.02 and $173.73 today. Over the past year, it has seen a low of $79.19 and a high of $184.40, indicating significant volatility.
The company has a market capitalization of approximately $8.60 billion. Despite a negative price-to-earnings (P/E) ratio of -38.26, the price-to-earnings-growth ratio stands at 16.17. Axsome's financial health is supported by a debt-to-equity ratio of 1.66, a quick ratio of 1.50, and a current ratio of 1.57, suggesting a stable liquidity position.
|
DVLT§>
Datavault AI Inc.
|
$0.56
-24.71%
|
|
TZA§>
Direxion Daily Small Cap Bear 3X ETF
|
$4.97
1.43%
|
|
CHSN§>
Chanson International Holding
|
$0.03
3.15%
|
|
DEVS§>
DevvStream Corp. Common Stock
|
$0.22
-28.42%
|
|
BITO§>
ProShares - Bitcoin ETF
|
$10.95
1.96%
|
|
SOXS§>
Direxion Daily Semiconductor Bear 3X ETF
|
$13.26
2.16%
|
|
NVDA§>
NVIDIA Corporation
|
$198.48
0.02%
|
|
INTC§>
Intel Corporation
|
$95.78
-3.85%
|
|
NOK§>
Nokia Oyj
|
$13.13
-1.28%
|
|
MNDR§>
Mobile-health Network Solutions Class A Ordinary Shares
|
$1.20
26.32%
|